JonesTrading analyst Boris Peaker initiated coverage of biopharmaceutical company Adlai Nortye (ANL) with a "Buy" rating and a $22 price target, projecting a 46.5% upside over one year. Wall Street's consensus rating is "Strong Buy," with an average price target of $24.67, implying a 64% upside over one year. ANL shares are currently trading at $15.01, having risen 957% year-to-date.